Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils

Save

Report Abuse

Description

It is planned to recruit about 100 pathologically confirmed subjects with advanced solid tumors (non-small cell lung cancer, breast cancer, ovarian cancer, stomach cancer, colorectal cancer, pancreatic cancer, mesothelioma, etc.) that have progressed after standard second-line or above treatment such as surgery, chemoradiotherapy, targeted therapy and PD-1 antibody therapy. A single infusion of human granulocytes with anti-cancer mouse characteristics was performed for 5 consecutive transfusions at a interval of 2±1 day, and the safety and efficacy were clinically observed. After the investigator's judgment and discussion with the sponsor, more cycles of treatment can be received after the informed consent is completed until the criteria for stopping treatment are met.

Study Overview

Start Date
November 1, 2023
Completion Date
December 31, 2025
Enrollment
18
Date Posted
February 5, 2024
Accepts Healthy Volunteers?
No
Gender
All

Locations

Full Address
Wuxi People's Hospital
Wuxi, Jiangsu 214043, China

Eligibility

Minimum Age (years)
18
Maximum Age (years)
75
Eligibility Criteria
Inclusion Criteria:

Age 18 ~ 75 years old (inclusive), gender is not limited
Malignant tumor confirmed by puncture pathology/postoperative pathology, or PET-CT multi-focal high signal, clinical stage IV
Physical status score of 0-2 in ECOG scale
Expected survival time ≥3 months
Have measurable lesions, calculate the sum of the longest diameter of all target lesions, and report as the baseline sum diameter: the lesions can be accurately measured in at least one direction (record the longest diameter), as long as it conforms to RECIST1.1; If there are multiple lesions, a maximum of 5 lesions (no more than 2 per organ) are required; The efficacy of hematological malignancies such as leukemia can be confirmed by cytology/histology
more than 4 weeks have elapsed since previous drug therapy, radiation therapy and surgery; Oral fluorouracil and small molecule targeted drugs required for more than 2 weeks or within 5 half-lives of the drug (whichever is longer)
Laboratory tests meet the following criteria: (1) Bone marrow function: absolute count of blood neutrophils (ANC) ≥1*10^9/L, platelets (PLT) ≥75*10^9/L; (2) Liver function: serum total bilirubin (STB), bound bilirubin (CB) ≤ upper limit of normal (ULN) *1.5, alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ULN*2.5 (in the absence of liver metastasis), or ≤ULN*5 (in the presence of liver metastasis); (3) Kidney function: serum creatinine (Cr) ≤ULN*1.5, endogenous creatinine clearance (Ccr) ≥50 mL/min (calculated by Cockcroft-Gault formula)
Anti-neutrophil antibody test results are negative
The patient volunteered and signed the informed consent

Exclusion Criteria:

1: Uncontrolled or severe cardiovascular disease, diabetes, major heart disease, such as arrhythmia within 30 days, congestive heart failure, or severe coronary artery disease

2: HIV infection, no recent (within 30 days) use of immunosuppressive drugs other than steroids

3: Pregnant and lactating women

4: Previous history of stem cell and organ transplantation

5: Patients who have been using or are using immunosuppressants for a long time

6: Symptomatic brain metastases are not controlled

7: People who are known to be severely allergic to granulocyte infusion (or test positive for anti-neutrophil antibodies)

8: People with coagulation disorders

9: Mental disorders are not under control

10: Patients with severe autoimmune diseases

11: Cases deemed unsuitable for inclusion by the investigator

Study Contact Info

Study Contact Name
Peihua Lu, Doctor
Study Contact Email
Study Contact Phone

Contact Listings Owner Form

Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
No
FDA Regulated Device?
No
Detailed Description
100 cases of advanced cancer with failed chemotherapy or ineffective standard treatment or relief measures were enrolled and clinically observed. Single infusion dose 2.0-5.0 × 1010 granulocytes were continuously infused 5 times every 2 ± 1 day. According to the patient's condition, ensure that the number of subjects with a single tumor is not less than 20.
NCTid (if applicable)
NCT06240767